PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 19/00, C12N 15/62, 15/70, 1/21

A2

(11) International Publication Number: **WO 00/24782**

(43) International Publication Date: 4 May 2000 (04.05.00)

(21) International Application Number: PCT/US99/25044

(22) International Filing Date: 25 October 1999 (25.10.99)

(30) Priority Data:

60/105,371	23 October 1998 (23.10.98)	US
09/428,082	22 October 1999 (22.10.99)	US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320–1799 (US).

(72) Inventors: FEIGE, Ulrich; 3117 Deer Valley Avenue, Newbury Park, CA 91320 (US). LIU, Chuan–Fa; 1425 Clover Creek Drive, Longmont, CO 80503 (US). CHEETHAM, Janet; 1695 East Valley Road, Montecito, CA 93108 (US). BOONE, Thomas, Charles; 3010 Deer Valley Avenue, Newbury Park, CA 91320 (US).

(74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320–1799 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

(57) Abstract

The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half–life of the peptide, which otherwise would be quickly degraded *in vivo*. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, *E. coli* display, ribosome display, RNA–peptide screening, or chemical–peptide screening.